A NYT article has Wall Street abuzz today with whispers of non-profit hospital groups creating a new generics maker or partnering with third party manufacturers.
Though BTIG’s Tim Chiang sees a recovery in the works for TEVA, he sees shares as “fairly valued” at currently levels.
Guggenheim’s Rohit Vanjani reacts to the debt rating downgrade on Teva from the sidelines without shock, having seen the writing on the wall.
Goldman Sachs’ Jami Rubin now spotlights 16% return potential for TEVA shares, putting his bet on the Israeli pharma giant’s recovery.
Mizuho’s Irina Rivkind Koffler is leaving the sidelines on Teba and boosting her price target, now angling for 19% upside.
Though in the next 12 months, Cantor’s Louise Chen is hesitant to take a gamble on an Israeli biotech giant just at the beginning of a comeback, she likes what she sees in new TEVA CEO Kare Schultz’s strategy.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been hit with recent negative sentiment on its home front in Israel, as the company deals …
Mizuho’s Irina Rivkind reflects on how much Teva’s cost cutting compare to expectations; The missing puzzle piece – revenue guidance.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced this morning the exclusive US launch of Viread®1 (tenofovir disoproxil fumarate) tablets 300 mg, a generic …
Cost cutting is great, but the benefits have been quickly priced into the stock.
